Author

Manish R. Sharma

ORCID: 0009-0000-9769-0850

Observed ORCID: 0009-0000-9769-0850

OpenAlex ID: A5137302010

A phase 1, first-in-human (FIH) study evaluating the safety, pharmacokinetics, and efficacy of ABBV-969 in patients with metastatic castration-resistant prostate cancer (mCRPC).

2026 · Tanya B. Dorff, Avivit Peer, et al. · Journal of Clinical Oncology · 3

A phase 1/2, first-in-human, open-label, dose-escalation and -expansion study of TAK-188, a novel antibody-drug conjugate (ADC) targeting CCR8 + regulatory T cells, in adult patients with locally advanced or metastatic solid tumors.

2026 · Anthony J. Olszanski, Drew W. Rasco, et al. · Journal of Clinical Oncology · 1

A phase 1, first-in-human (FIH), dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 T-cell engager in participants with advanced or metastatic microsatellite-stable (MSS)/microsatellite instability–low (MSI-L) colorectal cancer (CRC).

2026 · Alexander I. Spira, David Sommerhalder, et al. · Journal of Clinical Oncology · 1

Eiu-104101: A first-in-human phase 1a/1b study of EVOLVE104, a trispecific CD3×CD2×ULBP2/5/6 T-cell engager, in advanced urothelial and squamous cell carcinomas.

2026 · Tony Fiorino, Manish R. Sharma, et al. · Journal of Clinical Oncology · 1

Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors

2026 · Jong Chul Park, David Berz, et al. · Cancer Research Communications · 1

A phase 1/2, open-label study of oral S241656 (BDTX-4933) as monotherapy and in combination with other anti-cancer therapies in patients with KRAS, BRAF and other selected RAS/MAPK mutation positive malignancies.

2026 · Ajay Prakash, Michael Offin, et al. · Journal of Clinical Oncology · 1

A phase 1 study of HWK-007, a next-generation, protein tyrosine kinase 7 (PTK7)–targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors.

2026 · Manish R. Sharma, Jennifer Margaret Segar, et al. · Journal of Clinical Oncology

Phase I/II study of AZD6750, a CD8-guided interleukin-2 agent, alone and in combination with other anti-cancer agents in participants with advanced or metastatic solid tumors.

2026 · Drew W. Rasco, Shigehiro Koganemaru, et al. · Journal of Clinical Oncology

Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein–targeting antibody-drug conjugate: Results from patients with head and neck squamous cell carcinoma (HNSCC).

2026 · Victoria Meucci Villaflor, James J. Harding, et al. · Journal of Clinical Oncology

A phase 1, first-in-human study of OP-3136, a novel oral selective KAT6A/B inhibitor, as monotherapy in advanced solid tumors and in combination with endocrine therapy in ER+, HER2− advanced breast cancer (ABC): Preliminary results.

2026 · Amita Patnaik, Manish R. Sharma, et al. · Journal of Clinical Oncology

Works count: 10

Citation count: 8

H-index: 1

I10-index: